Newsletter Subject

Don't Let Panic Get the Best of You

From

wealthdaily.com

Email Address

newsletter@wealthdaily.com

Sent On

Tue, Nov 30, 2021 02:12 PM

Email Preheader Text

A new COVID-19 variant, Omicron, has emerged and is creating panic throughout the world at a time wh

A new COVID-19 variant, Omicron, has emerged and is creating panic throughout the world at a time when COVID fatigue is at an all-time high. Don’t let fear get the best of you because science and biotechs are working hard to develop treatments and products to fight against this virus. A new COVID-19 variant, Omicron, has emerged and is creating panic throughout the world at a time when COVID fatigue is at an all-time high. Don’t let fear get the best of you because science and biotechs are working hard to develop treatments and products to fight against this virus. [Wealth Daily logo] Don't Let Panic Get the Best of You [Monica Savaglia Photo] By [Monica Savaglia]( Written Nov 30, 2021 Just when we were starting to feel a little more optimistic about COVID there’s another variant that could pose a threat to the U.S. and the world. Market volatility is the last thing that we want to end on this year. We're all aware of how this pandemic has been extremely disruptive. No one wants to go back to lockdowns or other extreme restrictions again. We are burnt out. This is why I’m not surprised that the market is experiencing the after-effects of the recent news of the Omicron variant. No one knows what to expect and most are expecting the worst. I’d be lying if I said it’s hard not to feel that way since we have endured so much in the past two years. However, I don’t believe we’re at the same spot as we were back in February and March of 2020. Not to put it lightly since we’ve all been through a lot (and more than others), but we’ve managed to adjust our lives around the coronavirus and its variants in order to do what we need to do to survive. Our resilience is obvious. So while I do believe that we should be a little cautious of what’s going on and take note, I don’t think it would be in anyone’s best interests to act irrationally. We all want to come out at the end of this pandemic. I know it can be hard to remain optimistic but I know we'll get there. Especially when we have science on our side to help. Are We Far From 2020? That’s the difference between 2020 and now — we have treatments and vaccines that are helping us fight this pandemic with all that we've got. Getting to the end of this COVID pandemic is what we all want. Biotech companies have been working hard these past two years to achieve just that. And now, they are continuing those efforts to help protect people from this recent variant. Jesse Bloom, an evolutionary biologist at the Fred Hutchinson Cancer Research Center in Seattle told the New York Times: We really need to be vigilant about this new variant and preparing for it. Probably in a few weeks, we’ll have a better sense of how much this variant is spreading and how necessary it might be to push forward with a variant vaccine. At the moment, many experts are unsure of what kind of damage this variant might be able to do and if current vaccines would be effective. That’s why vaccine makers Moderna, Pfizer-BioNTech, and Johnson & Johnson are preparing to reformulate their shots if necessary so that that reformulation would be available to the public when and if necessary. In a news release on Friday, Moderna said: The recently described Omicron variant included mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen in the Beta and Delta variants that are believed to promote immune escape. The combination of mutations represents a significant potential risk to accelerate the waning of natural and vaccine-induced immunity. We know mRNA vaccines like the ones from Moderna and Pfizer-BioNTech can adapt. A Pfizer spokeswoman, Jerica Pitts, said scientists “can adopt the current vaccine within six weeks and ship initial batches within 100 days in the event of an escape variant.” Scientists and health experts are doing what they have been doing throughout this entire pandemic — urging the public to wear masks, avoid crowded spaces, get vaccinated, get boosters if they are available to you. Facebook Has Already Bet $50 Billion on ThisForget 5G — 2021’s Biggest Gains Will Be Here Mark Zuckerberg is no fool. So when he invests $50 billion in a brand-new technology, you'd better pay attention — especially when venture capitalists have also plowed $45 billion in it. Apple and Google have quietly added it to more than 1 billion smartphones. And this exclusive video reveals why this new tech breakthrough is about to revolutionize the computing world... and make a lot of people very rich. Early investors stand to make extraordinary gains of as much as 9,910%. But you have to hurry — this technology is about to go mainstream. [Go here now to get the inside story.]( Don't Panic — We Got Science Behind Us On Monday, President Biden spoke to the country about the Omicron variant saying, “This variant is a cause for concern — not a cause for panic.” The Omicron variant is just another realization of how COVID-19 is here to stay — at least for now. As tiring as it may sound, we will need to continue to take action against this virus with various treatments, whether that be with vaccines or other treatments that can kill symptoms and severe illness and death. I know people want to get back to life pre-pandemic, but building up immunity to this virus and ensuring that the spread of the virus is contained is crucial to getting back to a time where we don’t have to worry about variants disrupting our everyday lives. And speaking of preventing the spread, there's a small biotech company that is producing a nasal spray with the ability to stop COVID-19 symptoms in seven days. This nasal spray is part of these other remarkable scientific discoveries that are helping the world get past COVID-19. The interesting thing about this nasal spray company is that it’s relatively unknown, kind of similar to Moderna before it came out with its COVID-19 vaccine. Now Moderna is up over 2,000% since March 2020. This [COVID-killing nasal spray company]( is expected to rise within the next year as it could get fast-track approval, which could easily put the company on track to similar gains to what Moderna has experienced over the past year with its COVID-fighting vaccine. The small company could be on track to developing and producing one of the biggest medical breakthroughs — especially at a time when we need it the most. One of the best things to come out of this pandemic is having the opportunity to invest in companies like this COVID-killing nasal spray company. I wish I could talk to you more about it today, but I just don't have the time. There’s so much more that you need to know and I’m barely scratching the surface with this article. So if you've got time to spare today and want to learn more, [check out this report](. You'll learn more about this COVID-killing nasal spray and what lies ahead for the company that’s developing this groundbreaking product. Until next time, [Monica Savaglia Signature Park Avenue Digest] Monica Savaglia --------------------------------------------------------------- The Big Announcement Is in 9 Days Studies are showing that in most ways, women age better than men do. For every three women that reach 80, only one man does. Steven Austad, an expert on aging at the University of Alabama at Birmingham, said it best... “If we could find a way to make men live as long as women and make women be as healthy as men later in life, then we would have an enormous impact on our lives.” Little does he know that a certain company will announce something absolutely groundbreaking on December 9, 2021… This company could unlock one of the biggest medical wonders in human history. With this technology, both men and women may never have to worry about aging. And the small number of investors who get in on this company before the big announcement on December 9 stand to rake in massive windfalls. [All the details on this company are right here in my report.]( Browse Our Archives [Please Prepare Your Portfolio for Liftoff]( [Make Your Portfolio Fatter Than a Thanksgiving Turkey]( [Let's Give Thanks to Science]( [How to Get Paid Every Black Friday]( ["Don't Urinate on My Leg and Tell Me It's Raining"]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Wealth Daily, please add newsletter@wealthdaily.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. Wealth Daily, Copyright © 2021, Angel Publishing LLC. All rights reserved. 3 E Read Street, Baltimore, MD 21202. Your privacy is important to us – we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment advice. Read our [Details and Disclosures.](

Marketing emails from wealthdaily.com

View More
Sent On

08/12/2024

Sent On

03/12/2024

Sent On

02/12/2024

Sent On

28/11/2024

Sent On

10/11/2024

Sent On

07/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.